Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, World Health Organization Collaborating Centre for Non-Communicable Diseases, International Diabetes Federation Centre of Education, Gopalapuram, Chennai, India.
Diabetes Technol Ther. 2010 Aug;12(8):613-8. doi: 10.1089/dia.2010.0033.
This study reports on the effectiveness of exenatide compared to insulin glargine or NPH insulin in patients with type 2 diabetes mellitus, unable to achieve glycemic control with oral glucose-lowering therapies in a clinical care setting.
Patients with type 2 diabetes mellitus (n = 47) whose glycemia was not controlled adequately with oral hypoglycemic agents at maximum recommended therapeutic doses were initiated on exenatide therapy. Age-, sex-, and body mass index-matched patients receiving insulin glargine (n = 54) or NPH insulin (n = 23) served as controls. Data analysis included glycated hemoglobin, fasting and postprandial plasma glucose, lipid profile, body weight, and the occurrence of hypoglycemia.
A statistically significant reduction in glycated hemoglobin value was noted after initiating exenatide (pre-exenatide 9.7 +/- 1.4% vs. post-exenatide 8.7 +/- 1.5%; P < 0.05), which was comparable to values after insulin glargine (9.8 +/- 1.1% vs. 9.0 +/- 1.5%, respectively; P < 0.05) and NPH insulin (9.6 +/- 1.4% vs. 8.9 +/- 1.3%, respectively; P < 0.05). Exenatide therapy was associated with net weight loss (mean, 1.6 kg), but therapy with insulin glargine and NPH insulin was associated with weight gain (1.8 and 2.3 kg, respectively).
In a group of select Asian Indian type 2 diabetes patients with secondary failure to oral hypoglycemic agents seen at a diabetes center, exenatide treatment in combination with oral drug regimens resulted in significant lowering of glycated hemoglobin similar to insulin glargine or NPH insulin but with the additional benefit of weight loss, albeit a small amount.
本研究报告了在临床护理环境中，对于使用口服降糖药物治疗仍无法控制血糖的 2 型糖尿病患者，与甘精胰岛素或 NPH 胰岛素相比，艾塞那肽的有效性。
将血糖控制不佳（最大推荐治疗剂量的口服降糖药物）的 47 例 2 型糖尿病患者起始艾塞那肽治疗。年龄、性别和体重指数匹配的接受甘精胰岛素（n = 54）或 NPH 胰岛素（n = 23）治疗的患者作为对照。数据分析包括糖化血红蛋白、空腹和餐后血糖、血脂谱、体重和低血糖的发生情况。
起始艾塞那肽后，糖化血红蛋白值有显著降低（治疗前 9.7 ± 1.4% vs. 治疗后 8.7 ± 1.5%；P < 0.05），与甘精胰岛素（9.8 ± 1.1% vs. 9.0 ± 1.5%；P < 0.05）和 NPH 胰岛素（9.6 ± 1.4% vs. 8.9 ± 1.3%；P < 0.05）的结果相当。艾塞那肽治疗与体重净减轻（平均 1.6 kg）相关，但甘精胰岛素和 NPH 胰岛素治疗与体重增加（分别为 1.8 和 2.3 kg）相关。
在一个糖尿病中心就诊的继发性口服降糖药物治疗失败的特定亚洲印度 2 型糖尿病患者中，艾塞那肽治疗与口服药物治疗联合使用可显著降低糖化血红蛋白，与甘精胰岛素或 NPH 胰岛素相似，但有额外的体重减轻获益，尽管获益量较小。
